| Name | Title | Contact Details |
|---|
William S. Hein & Co., Inc. has been serving the library community for more than 100 years as a legal publisher, periodical subscription agent, and the worlds largest distributor of legal periodicals. Heins research and reference tools for law, international relations, political science, and foreign affairs are among its most important contributions to the publishing world. Heins premier online database, HeinOnline, is an online research platform that provides more than 233 million pages of multidisciplinary periodicals, essential government documents, international resources, case law, and much more. Composed of fully searchable image-based PDFs and available at an affordable price, the wealth of material allows academic institutions, government agencies, law firms, court systems, corporations, and other organizations access to authoritative, true-to-print digital material without the hassle or cost of using multiple research databases. Every document across HeinOnlines 100+ databases is an exact facsimile of its print counterpart, providing access to original, authoritative sources as well as the ease and speed that accompanies online searching. To improve the discoverability of relevant content, weve also incorporated unique artificial intelligence tools and research aids throughout our various databases.
Innovator ETFs is a company that provides visionary investment opportunities through their Defined Outcome ETFs, including Accelerated ETFs, Buffer ETFs, Bond ETFs, and Stacker ETFs.
Digital Means is a North York, ON-based company in the Business Services sector.
Hr Dynamics Inc is a New York, NY-based company in the Business Services sector.
Javara Inc., is a next generation Integrated Research Organization (IRO) designed to engage innovative research partnerships and deploy comprehensive research service offerings to healthcare systems. Together, Javara and their healthcare partners will offer a more aligned, efficient, and effective solution to the challenges of patient inclusion in the ever-increasing complexity and cost of drug development.